This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thukral, S. K.
Right arrow Articles by Jacobsen, V. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thukral, S. K.
Right arrow Articles by Jacobsen, V. L.

 Previous Article

Mol. Cell. Biol., 09 1995, 5196-5202, Vol 15, No. 9
Copyright © 1995, American Society for Microbiology

Discrimination of DNA binding sites by mutant p53 proteins

SK Thukral, Y Lu, GC Blain, TS Harvey and VL Jacobsen
Department of Developmental Biology, Amgen, Thousand Oaks, California 91320, USA.

Critical determinants of DNA recognition by p53 have been identified by a molecular genetic approach. The wild-type human p53 fragment containing amino acids 71 to 330 (p53(71-330)) was used for in vitro DNA binding assays, and full-length human p53 was used for transactivation assays with Saccharomyces cerevisiae. First, we defined the DNA binding specificity of the wild-type p53 fragment by using systematically altered forms of a known consensus DNA site. This refinement indicates that p53 binds with high affinity to two repeats of PuGPuCA.TGPyCPy, a further refinement of an earlier defined consensus half site PuPuPuC(A/T).(T/A) GPyPyPy. These results were further confirmed by transactivation assays of yeast by using full- length human p53 and systematically altered DNA sites. Dimers of the pentamer AGGCA oriented either head-to-head or tail-to-tail bound efficiently, but transactivation was facilitated only through head-to- head dimers. To determine the origins of specificity in DNA binding by p53, we identified mutations that lead to altered specificities of DNA binding. Single-amino-acid substitutions were made at several positions within the DNA binding domain of p53, and this set of p53 point mutants were tested with DNA site variants for DNA binding. DNA binding analyses showed that the mutants Lys-120 to Asn, Cys-277 to Gln or Arg, and Arg-283 to Gln bind to sites with noncanonical base pair changes at positions 2, 3, and 1 in the pentamer (PuGPuCA), respectively. Thus, we implicate these residues in amino acid-base pair contacts. Interestingly, mutant Cys-277 to Gln bound a consensus site as two and four monomers, as opposed to the wild-type p53 fragment, which invariably binds this site as four monomers.


This article has been cited by other articles:

  • Wei, G., Li, A. G., Liu, X. (2005). Insights into Selective Activation of p53 DNA Binding by c-Abl. J. Biol. Chem. 280: 12271-12278 [Abstract] [Full Text]  
  • Inga, A., Storici, F., Darden, T. A., Resnick, M. A. (2002). Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence. Mol. Cell. Biol. 22: 8612-8625 [Abstract] [Full Text]  
  • Buzek, J., Latonen, L., Kurki, S., Peltonen, K., Laiho, M. (2002). Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. Nucleic Acids Res 30: 2340-2348 [Abstract] [Full Text]  
  • Fulci, G., Ishii, N., Maurici, D., Gernert, K. M., Hainaut, P., Kaur, B., Van Meir, E. G. (2002). Initiation of Human Astrocytoma by Clonal Evolution of Cells with Progressive Loss of p53 Functions in a Patient with a 283H TP53 Germ-line Mutation: Evidence for a Precursor Lesion. Cancer Res. 62: 2897-2905 [Abstract] [Full Text]  
  • Robert, V., Michel, P., Flaman, J. M., Chiron, A., Martin, C., Charbonnier, F., Paillot, B., Frebourg, T. (2000). High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis. Carcinogenesis 21: 563-565 [Abstract] [Full Text]  
  • Tan, M., Li, S., Swaroop, M., Guan, K., Oberley, L. W., Sun, Y. (1999). Transcriptional Activation of the Human Glutathione Peroxidase Promoter by p53. J. Biol. Chem. 274: 12061-12066 [Abstract] [Full Text]  
  • Kelavkar, U. P., Badr, K. F. (1999). Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: Evidence that 15-lipoxygenase is a mutator gene. Proc. Natl. Acad. Sci. USA 96: 4378-4383 [Abstract] [Full Text]  
  • Mathupala, S. P., Heese, C., Pedersen, P. L. (1997). Glucose Catabolism in Cancer Cells. THE TYPE II HEXOKINASE PROMOTER CONTAINS FUNCTIONALLY ACTIVE RESPONSE ELEMENTS FOR THE TUMOR SUPPRESSOR p53. J. Biol. Chem. 272: 22776-22780 [Abstract] [Full Text]  
  • Nagaich, A. K., Zhurkin, V. B., Sakamoto, H., Gorin, A. A., Clore, G. M., Gronenborn, A. M., Appella, E., Harrington, R. E. (1997). Architectural Accommodation in the Complex of Four p53 DNA Binding Domain Peptides with the p21/waf1/cip1 DNA Response Element. J. Biol. Chem. 272: 14830-14841 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»